Related Experiment Video
Updated: Jul 6, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Immunotherapeutic treatment strategies for primary brain tumors
Sunit Das1, Jeffrey J Raizer, Kenji Muro
1Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, 676 North St. Clair Street, Suite 2210, Chicago, IL 60611, USA.
Opinion Statement:
Primary brain tumors account for a minor fraction of cancer diagnoses made worldwide and remain one of the most difficult to treat. Despite ongoing efforts to improve the quality of life and overall survival of these patients, current multimodality therapy has achieved only modest gains; the median survival is approximately 14 months among patients with the deadliest form of primary brain tumor, glioblastoma multiforme. Although the brain has been long considered an immunologically privileged organ, there is increased awareness of and appreciation for the complex interplay between the nervous system and the immune system in the setting of many disease states, including neoplastic. Although the concept of harnessing the specificity, activity, and memory of the immune system toward the treatment of brain tumors has been in existence for several decades and the neuro-oncology literature holds many publications that once promised of a breakthrough, only recently has a strategy emerged that addresses many of the limitations identified through past failures. It is with cautious optimism that the authors review the past and discuss the present status of immunotherapy and its role in the management of patients with primary brain tumors.
Insights
Immunotherapy offers new hope for treating primary brain tumors, including glioblastoma. Recent advancements address limitations of past approaches, potentially improving patient survival and quality of life.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Research
Background:
- Primary brain tumors are rare but challenging to treat, with glioblastoma having a median survival of only 14 months.
- The brain's immune privilege is being re-evaluated, revealing a complex neuro-immune system interplay in cancer.
- Decades of research in brain tumor immunotherapy have faced limitations, hindering clinical breakthroughs.
Purpose of the Study:
- To review the historical context and current status of immunotherapy for primary brain tumors.
- To discuss the potential of novel immunotherapy strategies in neuro-oncology.
- To provide a cautiously optimistic outlook on immunotherapy's role in managing brain tumors.
Main Methods:
- Literature review of past and present immunotherapy research in primary brain tumors.
- Analysis of challenges and limitations encountered in previous treatment strategies.
- Discussion of emerging immunotherapy approaches and their potential benefits.
Main Results:
- Despite past challenges, recent immunotherapy strategies show promise in addressing limitations.
- The understanding of the neuro-immune system in brain tumors is evolving.
- New approaches are emerging that may overcome previous therapeutic hurdles.
Conclusions:
- Immunotherapy represents a cautiously optimistic frontier in primary brain tumor management.
- Recent advancements offer potential improvements in survival and quality of life for patients.
- Further research and clinical application of novel immunotherapies are warranted.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...